|
1
|
Videtic GM, Hu C, Singh AK, Chang JY,
Parker W, Olivier KR, Schild SE, Komaki R, Urbanic JJ, Timmerman RD
and Choy H: A randomized phase 2 study comparing 2 stereotactic
body radiation therapy schedules for medically inoperable patients
with stage i peripheral non-small cell lung cancer: NRG oncology
RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys. 93:757–764.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nie X, Cheng G, Ai B and Zhang S: The
tailored chemotherapy based on RRM1 immunohistochemical expression
in patients with advanced non-small cell lung cancer. Cancer
Biomark. 13:433–440. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karp DD, Lee SJ, Keller SM, Wright GS,
Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon
G, et al: Randomized, double-blind, placebo-controlled, phase III
chemoprevention trial of selenium supplementation in patients with
resected stage I non-small-cell lung cancer: ECOG 5597. J Clin
Oncol. 31:4179–4187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang R, Chen XF and Shu YQ: Prediction of
non-small cell lung cancer metastasis-associated microRNAs using
bioinformatics. Am J Cancer Res. 5:32–51. 2014.PubMed/NCBI
|
|
5
|
Sin TK, Wang F, Meng F, Wong SC, Cho WC,
Siu PM, Chan LW and Yung BY: Implications of MicroRNAs in the
treatment of gefitinib-resistant non-small cell lung cancer. Int J
Mol Sci. 17:2372016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen F, Hou SK, Fan HJ and Liu YF:
MiR-15a-16 represses Cripto and inhibits NSCLC cell progression.
Mol Cell Biochem. 391:11–19. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu N, Zhang C, Bai C, Han YP and Li Q:
MiR-4782-3p inhibited non-small cell lung cancer growth via USP14.
Cell Physiol Biochem. 33:457–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin R, Chen L, Chen G, Hu C, Jiang S,
Sevilla J, Wan Y, Sampson JH, Zhu B and Li QJ: Targeting miR-23a in
CD8+ cytotoxic T lymphocytes prevents tumor-dependent
immunosuppression. J Clin Invest. 124:5352–5367. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li N, Zhang F, Li S and Zhou S: Epigenetic
silencing of MicroRNA-503 regulates FANCA expression in non-small
cell lung cancer cell. Biochem Biophys Res Commun. 444:611–616.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Ling C, Bai Y and Zhao J:
MicroRNA-206 is associated with invasion and metastasis of lung
cancer. Anat Rec (Hoboken). 294:88–92. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Aghanoori MR, Mirzaei B and Tavallaei M:
MiRNA molecular profiles in human medical conditions: Connecting
lung cancer and lung development phenomena. Asian Pac J Cancer
Prev. 15:9557–9565. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dy GK, Hillman SL, Rowland KM Jr, Molina
JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE and Adjei
AA: North Central Cancer Treatment Group Study N0326: A front-line
window of opportunity phase 2 study of sorafenib in patients with
advanced nonsmall cell lung cancer: North central cancer treatment
group study N0326. Cancer. 116:5686–5693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mita AC, Papadopoulos K, de Jonge MJ,
Schwartz G, Verweij J, Mita MM, Ricart A, Chu QS, Tolcher AW, Wood
L, et al: Erlotinib ‘dosing-to-rash’: A phase II intrapatient dose
escalation and pharmacologic study of erlotinib in previously
treated advanced non-small cell lung cancer. Br J Cancer.
105:938–944. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Roa WH, Kim JO, Razzak R, Du H, Guo L,
Singh R, Gazala S, Ghosh S, Wong E, Joy AA, et al: Sputum microRNA
profiling: A novel approach for the early detection of non-small
cell lung cancer. Clin Invest Med. 35:E2712012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang W, Winder T, Ning Y, Pohl A, Yang D,
Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, et al: A let-7
microRNA-binding site polymorphism in 3′-untranslated region of
KRAS gene predicts response in wild-type KRAS patients with
metastatic colorectal cancer treated with cetuximab monotherapy.
Ann Oncol. 22:104–109. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Karachaliou N, Rosell R, Morales-Espinosa
D and Viteri S: Systemic treatment in EGFR-ALK NSCLC patients:
Second line therapy and beyond. Expert Rev Anticancer Ther.
14:807–815. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Janmaat ML, Rodriguez JA, Gallegos-Ruiz M,
Kruyt FA and Giaccone G: Enhanced cytotoxicity induced by gefitinib
and specific inhibitors of the Ras or phosphatidyl inositol-3
kinase pathways in non-small cell lung cancer cells. Int J Cancer.
118:209–214. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Raben D, Helfrich B and Bunn PA Jr:
Targeted therapies for non-small-cell lung cancer: Biology,
rationale, and preclinical results from a radiation oncology
perspective. Int J Radiat Oncol Biol Phys. 59 2 Suppl:S27–S38.
2004. View Article : Google Scholar
|
|
20
|
Cui W, Zhang S, Shan C, Zhou L and Zhou Z:
microRNA-133a regulates the cell cycle and proliferation of breast
cancer cells by targeting epidermal growth factor receptor through
the EGFR/Akt signaling pathway. FEBS J. 280:3962–3974. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Song X, Shi B, Huang K and Zhang W:
miR-133a inhibits cervical cancer growth by targeting EGFR. Oncol
Rep. 34:1573–1580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhen Y, Li D, Li W, Yao W, Wu A, Huang J,
Gu H, Huang Y, Wang Y, Wu J, et al: Reduced PDCD4 expression
promotes cell growth through PI3K/Akt signaling in non-small cell
lung cancer. Oncol Res. 23:61–68. 2016. View Article : Google Scholar
|
|
23
|
Cheng H, Shcherba M, Pendurti G, Liang Y,
Piperdi B and Perez-Soler R: Targeting the PI3K/AKT/mTOR pathway:
Potential for lung cancer treatment. Lung Cancer Manag. 3:67–75.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong M, Yang G, Liu H, Liu X, Lin S, Sun D
and Wang Y: Aged black garlic extract inhibits HT29 colon cancer
cell growth via the PI3K/Akt signaling pathway. Biomed Rep.
2:250–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang H, Wu C, Wan S, Zhang H, Zhou S and
Liu G: Shikonin attenuates lung cancer cell adhesion to
extracellular matrix and metastasis by inhibiting integrin β1
expression and the ERK1/2 signaling pathway. Toxicology.
308:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zinn RL, Gardner EE, Marchionni L, Murphy
SC, Dobromilskaya I, Hann CL and Rudin CM: ERK phosphorylation is
predictive of resistance to IGF-1R inhibition in small cell lung
cancer. Mol Cancer Ther. 12:1131–1139. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao S, Wu J, Zheng F, Tang Q, Yang L, Li
L, Wu W and Hann SS: β-elemene inhibited expression of DNA
methyltransferase 1 through activation of ERK1/2 and AMPKα
signalling pathways in human lung cancer cells: the role of Sp1. J
Cell Mol Med. 19:630–641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao J, Zhao Y, Lv Y, Chen Y, Wei B, Tian
J, Yang Z, Kong F, Pang J, Liu J and Shi H: Mirk/Dyrk1B mediates
G0/G1 to S phase cell cycle progression and cell survival involving
MAPK/ERK signaling in human cancer cells. Cancer Cell Int.
13:22013. View Article : Google Scholar : PubMed/NCBI
|
